File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma

TitleEfficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
Authors
KeywordsAdvanced hepatocellular carcinoma
Anti-angiogenesis
Thalidomide
Issue Date2007
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCL
Citation
Oncology, 2007, v. 72 suppl. 1, p. 67-71 How to Cite?
AbstractObjective: The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far. HCC is a hypervascular tumor with over-expression of angiogenic factors such as vascular endothelial growth factor. Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action. We aim to evaluate the efficacy and toxicity of low-dose (100 mg) thalidomide as the first-line treatment of advanced HCC. Methods: Between August 2003 and March 2007, 45 patients who had received thalidomide 100 mg daily as first-line treatment of advanced HCC were reviewed retrospectively. Advanced HCC was defined as either metastatic or not amenable to surgical or locoregional therapies. Diagnosis of HCC was based on clinical, biochemical and radiological grounds. Survival was analyzed by the Kaplan-Meier method. Results: Thirty-eight patients were evaluable for response and toxicity. Two (5%) patients had partial response and 8 (21%) had stable disease. The overall median survival of patients in this cohort was 3.2 months (95% CI: 2.8-3.7 months). The common toxicities were somnolence (13%), peripheral neuropathy (11%) and ankle edema (8%), with no grade 3 or 4 toxicities and treatment-related deaths. Conclusion: Our study shows that a single agent, low-dose thalidomide has a modest clinical activity with good tolerability in treating advanced HCC patients. Copyright © 2007 S. Karger AG.
DescriptionThis journal suppl. entitled: Recent Progress in Hepatocellular Carcinoma 2007: 90-year Anniversary Issue of Katsusaburo Yamagiwa's Innovative Achievement on Carcinogenesis
Persistent Identifierhttp://hdl.handle.net/10722/76712
ISBN
ISSN
2015 Impact Factor: 2.152
2015 SCImago Journal Rankings: 0.920
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorWong, Hen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorLam, Ven_HK
dc.contributor.authorEpstein, RJen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T07:24:08Z-
dc.date.available2010-09-06T07:24:08Z-
dc.date.issued2007en_HK
dc.identifier.citationOncology, 2007, v. 72 suppl. 1, p. 67-71en_HK
dc.identifier.isbn978-3-8055-8413-5-
dc.identifier.issn0030-2414en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76712-
dc.descriptionThis journal suppl. entitled: Recent Progress in Hepatocellular Carcinoma 2007: 90-year Anniversary Issue of Katsusaburo Yamagiwa's Innovative Achievement on Carcinogenesis-
dc.description.abstractObjective: The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far. HCC is a hypervascular tumor with over-expression of angiogenic factors such as vascular endothelial growth factor. Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action. We aim to evaluate the efficacy and toxicity of low-dose (100 mg) thalidomide as the first-line treatment of advanced HCC. Methods: Between August 2003 and March 2007, 45 patients who had received thalidomide 100 mg daily as first-line treatment of advanced HCC were reviewed retrospectively. Advanced HCC was defined as either metastatic or not amenable to surgical or locoregional therapies. Diagnosis of HCC was based on clinical, biochemical and radiological grounds. Survival was analyzed by the Kaplan-Meier method. Results: Thirty-eight patients were evaluable for response and toxicity. Two (5%) patients had partial response and 8 (21%) had stable disease. The overall median survival of patients in this cohort was 3.2 months (95% CI: 2.8-3.7 months). The common toxicities were somnolence (13%), peripheral neuropathy (11%) and ankle edema (8%), with no grade 3 or 4 toxicities and treatment-related deaths. Conclusion: Our study shows that a single agent, low-dose thalidomide has a modest clinical activity with good tolerability in treating advanced HCC patients. Copyright © 2007 S. Karger AG.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCLen_HK
dc.relation.ispartofOncologyen_HK
dc.rightsOncology. Copyright © S Karger AG.en_HK
dc.subjectAdvanced hepatocellular carcinomaen_HK
dc.subjectAnti-angiogenesisen_HK
dc.subjectThalidomideen_HK
dc.titleEfficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0030-2414&volume=72 Suppl 1&spage=67&epage=71&date=2007&atitle=Efficacy+and+tolerability+of+low-dose+thalidomide+as+first-line+systemic+treatment+of+patients+with+advanced+hepatocellular+carcinomaen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailEpstein, RJ: repstein@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000111709en_HK
dc.identifier.pmid18087184-
dc.identifier.scopuseid_2-s2.0-37149051789en_HK
dc.identifier.hkuros140970en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-37149051789&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume72en_HK
dc.identifier.issuesuppl. 1en_HK
dc.identifier.spage67en_HK
dc.identifier.epage71en_HK
dc.identifier.isiWOS:000251663400009-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridWong, H=23089414000en_HK
dc.identifier.scopusauthoridNg, KK=7403179075en_HK
dc.identifier.scopusauthoridChok, SH=6602753231en_HK
dc.identifier.scopusauthoridCheung, TT=7103334165en_HK
dc.identifier.scopusauthoridLam, V=14828037100en_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats